INSERM, U978, Bobigny, France.
Université Paris 13 dite « Sorbonne Paris Nord », UFR SMBH, Labex INFLAMEX, Bobigny, France.
Cancer Gene Ther. 2023 Jul;30(7):1018-1028. doi: 10.1038/s41417-023-00602-5. Epub 2023 Mar 28.
Chronic Lymphocytic Leukemia (CLL) is a heterogeneous B cell neoplasm ranging from indolent to rapidly progressive disease. Leukemic cell subsets with regulatory properties evade immune clearance; however, the contribution of such subsets during CLL progression is not completely elucidated. Here, we report that CLL B cells crosstalk with their immune counterparts, notably by promoting the regulatory T (Treg) cell compartment and shaping several helper T (Th) subsets. Among various constitutively- and BCR/CD40-mediated factors secreted, tumour subsets co-express two important immunoregulatory cytokines, IL10 and TGFβ1, both associated with a memory B cell phenotype. Neutralizing secreted IL10 or inhibiting the TGFβ signalling pathway demonstrated that these cytokines are mainly involved in Th- and Treg differentiation/maintenance. In line with the regulatory subsets, we also demonstrated that a CLL B cell population expresses FOXP3, a marker of regulatory T cells. Analysis of IL10, TGFβ1 and FOXP3 positive subpopulations frequencies in CLL samples discriminated 2 clusters of untreated CLL patients that were significantly different in Tregs frequency and time-to-treatment. Since this distinction was pertinent to disease progression, the regulatory profiling provides a new rationale for patient stratification and sheds light on immune dysfunction in CLL.
慢性淋巴细胞白血病(CLL)是一种异质性 B 细胞肿瘤,从惰性到快速进展性疾病不等。具有调节特性的白血病细胞亚群逃避免疫清除;然而,这些亚群在 CLL 进展过程中的贡献尚未完全阐明。在这里,我们报告 CLL B 细胞与它们的免疫对应物相互作用,特别是通过促进调节性 T (Treg) 细胞区室和塑造几种辅助性 T (Th) 细胞亚群。在各种组成性和 BCR/CD40 介导的因子分泌中,肿瘤亚群共同表达两种重要的免疫调节细胞因子,IL10 和 TGFβ1,均与记忆 B 细胞表型相关。中和分泌的 IL10 或抑制 TGFβ 信号通路表明这些细胞因子主要参与 Th 和 Treg 的分化/维持。与调节性亚群一致,我们还证明了 CLL B 细胞群体表达 FOXP3,这是调节性 T 细胞的标志物。在未治疗的 CLL 样本中分析 IL10、TGFβ1 和 FOXP3 阳性亚群的频率可区分出 2 组未经治疗的 CLL 患者,它们在 Tregs 频率和治疗时间上存在显著差异。由于这种区别与疾病进展有关,因此调节分析为患者分层提供了新的依据,并阐明了 CLL 中的免疫功能障碍。